{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:39:27Z","timestamp":1740166767237,"version":"3.37.3"},"reference-count":24,"publisher":"Becaris Publishing Limited","issue":"12","funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Real-world treatment data for psoriatic arthritis are limited. We evaluated switch rates, adherence, and costs for patients initiating apremilast versus tumor necrosis factor inhibitor (TNFi) and interleukin inhibitor (ILi) among biologic-naive psoriatic arthritis patients.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            This retrospective analysis used IBM MarketScan claims data to assess treatment switches, adherence and costs.\n            <jats:bold>Results:<\/jats:bold>\n            Twelve-month switch rates were significantly lower for apremilast versus TNFi (15.5% vs 26.6%; p\u00a0&lt;\u00a00.0001) and similar to ILi (15.5% vs 14.0%; p\u00a0=\u00a00.71). Apremilast initiators had lower total costs versus TNFi and ILi (US$39,854 vs US$57,243 and US$65,687; p\u00a0&lt;\u00a00.05) and adherence was slightly lower versus TNFi and higher versus ILi.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Biologic-naive apremilast initiators had lower switch rates versus TNFi initiators and lower total costs versus TNFi or ILi initiators.\n          <\/jats:p>","DOI":"10.2217\/cer-2020-0285","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T08:14:15Z","timestamp":1625040855000},"page":"989-998","source":"Crossref","is-referenced-by-count":2,"title":["Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis"],"prefix":"10.57264","volume":"10","author":[{"given":"David L","family":"Kaplan","sequence":"first","affiliation":[{"name":"Adult &amp; Pediatric Dermatology, 4601 W 109th Street, Building Number 116, Overland Park, KS 66211, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian L","family":"Ung","sequence":"additional","affiliation":[{"name":"US HEOR, Bristol-Myers Squibb, 86 Morris Avenue, Summit, NJ 07901, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey","family":"Pelletier","sequence":"additional","affiliation":[{"name":"US HEOR, Bristol-Myers Squibb, 86 Morris Avenue, Summit, NJ 07901, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuka","family":"Udeze","sequence":"additional","affiliation":[{"name":"US HEOR, Celgene Corporation, 86 Morris Avenue, Summit, NJ\u00a007901, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Khilfeh","sequence":"additional","affiliation":[{"name":"Global Health Economics, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Tian","sequence":"additional","affiliation":[{"name":"US HEOR, Bristol-Myers Squibb, 86 Morris Avenue, Summit, NJ 07901, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"4","key":"e_1_3_6_3_2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie A","year":"2015","unstructured":"Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum. Dis. Clin. North Am. 41(4), 545\u2013568 (2015).","journal-title":"Rheum. Dis. Clin. North Am."},{"issue":"2","key":"e_1_3_6_4_2","first-page":"ii14","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman DD","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann. Rheum. Dis. 64(Suppl. 2), ii14\u2013ii17 (2005).","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"e_1_3_6_5_2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi F","year":"2019","unstructured":"Alinaghi F, Calov M, Kristensen LE Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J. Am. Acad. Dermatol. 80(1), 251\u2013265.e219 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"e_1_3_6_6_2","first-page":"122","article-title":"Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using U.S. administrative claims data","volume":"25","author":"Kaine J","year":"2019","unstructured":"Kaine J, Song X, Kim G Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using U.S. administrative claims data. J. Manag. Care Spec. Pharm. 25(1), 122\u2013132 (2019).","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"8","key":"e_1_3_6_7_2","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3899\/jrheum.121500","article-title":"Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis","volume":"40","author":"Husted JA","year":"2013","unstructured":"Husted JA, Thavaneswaran A, Chandran V Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. J. Rheumatol. 40(8), 1349\u20131356 (2013).","journal-title":"J. Rheumatol."},{"issue":"1","key":"e_1_3_6_8_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh JA","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 71(1), 5\u201332 (2019).","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"e_1_3_6_9_2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec L","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann. Rheum. Dis. 75(3), 499\u2013510 (2016).","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"e_1_3_6_10_2","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s10067-019-04446-z","article-title":"Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study","volume":"38","author":"Alten R","year":"2019","unstructured":"Alten R, Conaghan PG, Strand V Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study. Clin. Rheumatol. 38(6), 1615\u20131626 (2019).","journal-title":"Clin. Rheumatol."},{"key":"e_1_3_6_11_2","unstructured":"Otezla (apremilast) [package insert]. Amgen Inc. CA USA (2020). www.pi.amgen.com\/~\/media\/amgen\/repositorysites\/pi-amgen-com\/otezla\/otezla_pi_english.ashx"},{"issue":"6","key":"e_1_3_6_12_2","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a Phase III randomized, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh A","year":"2014","unstructured":"Kavanaugh A, Mease PJ, Gomez-Reino JJ Treatment of psoriatic arthritis in a Phase III randomized, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann. Rheum. Dis. 73(6), 1020\u20131026 (2014).","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"e_1_3_6_13_2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3899\/jrheum.140647","article-title":"Longterm (52-week) results of a Phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis","volume":"42","author":"Kavanaugh A","year":"2015","unstructured":"Kavanaugh A, Mease PJ, Gomez-Reino JJ Longterm (52-week) results of a Phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J. Rheumatol. 42(3), 479\u2013488 (2015).","journal-title":"J. Rheumatol."},{"issue":"6","key":"e_1_3_6_14_2","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a Phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards CJ","year":"2016","unstructured":"Edwards CJ, Blanco FJ, Crowley J Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a Phase III, randomised, controlled trial (PALACE 3). Ann. Rheum. Dis. 75(6), 1065\u20131073 (2016).","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"e_1_3_6_15_2","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s12325-016-0312-y","article-title":"A retrospective cohort study comparing utilization and costs of biologic therapies and JAK inhibitor therapy across four common inflammatory indications in adult US managed care patients","volume":"33","author":"Chastek B","year":"2016","unstructured":"Chastek B, White J, Van Voorhis D A retrospective cohort study comparing utilization and costs of biologic therapies and JAK inhibitor therapy across four common inflammatory indications in adult US managed care patients. Adv. Ther. 33(4), 626\u2013642 (2016).","journal-title":"Adv. Ther."},{"key":"e_1_3_6_16_2","first-page":"1","article-title":"Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis","author":"Wu JJ","year":"2019","unstructured":"Wu JJ, Pelletier C, Ung B Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis. Curr. Med. Res. Opin. 1\u20138 (2019).","journal-title":"Curr. Med. Res. Opin."},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2019-0034"},{"issue":"1","key":"e_1_3_6_18_2","doi-asserted-by":"crossref","first-page":"e000880","DOI":"10.1136\/rmdopen-2018-000880","article-title":"Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry","volume":"5","author":"Mease PJ","year":"2019","unstructured":"Mease PJ, Karki C, Liu M Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry. RMD Open 5(1), e000880 (2019).","journal-title":"RMD Open"},{"issue":"5","key":"e_1_3_6_19_2","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/acr.23337","article-title":"Patterns of systemic treatment for psoriatic arthritis in the US: 2004\u20132015","volume":"70","author":"Lee MP","year":"2018","unstructured":"Lee MP, Lii J, Jin Y Patterns of systemic treatment for psoriatic arthritis in the US: 2004\u20132015. Arthritis Care Res. (Hoboken) 70(5), 791\u2013796 (2018).","journal-title":"Arthritis Care Res. (Hoboken)"},{"issue":"5","key":"e_1_3_6_20_2","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","article-title":"Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey","volume":"70","author":"Lebwohl MG","year":"2014","unstructured":"Lebwohl MG, Bachelez H, Barker J Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J. Am. Acad. Dermatol. 70(5), 871\u2013881 (2014).","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_3_6_21_2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12891-016-1102-z","article-title":"Treatment patterns and costs for anti-TNFalpha biologic therapy in patients with psoriatic arthritis","volume":"17","author":"Palmer JB","year":"2016","unstructured":"Palmer JB, Li Y, Herrera V Treatment patterns and costs for anti-TNFalpha biologic therapy in patients with psoriatic arthritis. BMC Musculoskelet. Disord. 17, 261 (2016).","journal-title":"BMC Musculoskelet. Disord."},{"key":"e_1_3_6_22_2","first-page":"12369","article-title":"Switch rates and total cost of care associated with apremilast and biologic therapies in biologic-naive patients with plaque psoriasis","author":"Kaplan DL","year":"2020","unstructured":"Kaplan DL, Ung BL, Pelletier C Switch rates and total cost of care associated with apremilast and biologic therapies in biologic-naive patients with plaque psoriasis. ClinicoEcon. Outcomes Res. 12369\u201312377 (2020).","journal-title":"ClinicoEcon. Outcomes Res."},{"key":"e_1_3_6_23_2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3389\/fphar.2018.01540","article-title":"Is there a threshold for medication adherence? Lessons learnt from electronic monitoring of drug adherence","volume":"9","author":"Burnier M","year":"2018","unstructured":"Burnier M. Is there a threshold for medication adherence? Lessons learnt from electronic monitoring of drug adherence. Front. Pharmacol. 9, 1540 (2018).","journal-title":"Front. Pharmacol."},{"issue":"7","key":"e_1_3_6_24_2","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1007\/s10067-017-3636-3","article-title":"Economic impact of biologic utilization patterns in patients with psoriatic arthritis","volume":"36","author":"Schwartzman S","year":"2017","unstructured":"Schwartzman S, Li Y, Zhou H Economic impact of biologic utilization patterns in patients with psoriatic arthritis. Clin. Rheumatol. 36(7), 1579\u20131588 (2017).","journal-title":"Clin. Rheumatol."},{"issue":"5","key":"e_1_3_6_25_2","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/jdv.12742","article-title":"Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink.","volume":"29","author":"Edson-Heredia E","year":"2015","unstructured":"Edson-Heredia E, Zhu B, Lefevre C Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink. J. Eur. Acad. Dermatol. Venereol. 29(5), 955\u2013963 (2015).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"6","key":"e_1_3_6_26_2","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/acr.23910","article-title":"Impact of comorbidity on physical function in patients with ankylosing spondylitis and psoriatic arthritis attending rheumatology clinics: results from a cross-sectional study","volume":"72","author":"Fern\u00e1ndez-Carballido C","year":"2020","unstructured":"Fern\u00e1ndez-Carballido C, Mart\u00edn-Mart\u00ednez MA, Garc\u00eda-G\u00f3mez C Impact of comorbidity on physical function in patients with ankylosing spondylitis and psoriatic arthritis attending rheumatology clinics: results from a cross-sectional study. Arthritis Care Res. (Hoboken) 72(6), 822\u2013828 (2020).","journal-title":"Arthritis Care Res. (Hoboken)"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2020-0285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:15:26Z","timestamp":1679231726000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2020-0285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.2217\/cer-2020-0285"],"URL":"https:\/\/doi.org\/10.2217\/cer-2020-0285","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"type":"print","value":"2042-6305"},{"type":"electronic","value":"2042-6313"}],"subject":[],"published":{"date-parts":[[2021,8]]}}}